NewAmsterdam Pharma Company N.V.
NAMS
$36.40
-$0.07-0.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.48% | 57.85% | -86.23% | 64.68% | -1.87% |
| Total Depreciation and Amortization | 136.84% | 246.67% | 292.31% | 100.00% | 46.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 959.85% | -114.90% | 785.91% | -32.17% | -106.79% |
| Change in Net Operating Assets | -63.48% | 202.11% | -185.45% | 100.48% | -587.47% |
| Cash from Operations | 30.21% | 33.21% | -13.32% | 73.39% | -84.20% |
| Capital Expenditure | 57.89% | 95.84% | 0.00% | -733.33% | -4,080.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -76,041.63% | 841.56% | -2,072,533.33% | -733.33% | -4,080.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -26.47% | -95.94% | -- | -68.82% | -26.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -207.96% | -- | -- | -- |
| Cash from Financing | -26.47% | -96.71% | -- | -68.82% | -26.46% |
| Foreign Exchange rate Adjustments | 1,070.96% | 251.08% | -252.05% | 383.75% | 44.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -265.90% | -116.58% | 1,352.88% | 83.51% | -104.99% |